Procter & Gamble (P&G) is licensing its novel nasal swab to Rhinostics to launch and bring to the clinical laboratory market. P&G developed the swab as part of its commitment to help communities address supply shortages and to bring creative solutions to bear on the challenges facing laboratories and supply chains during the COVID-19 pandemic. The project was a collaboration between resources from P&G’s Personal Health Care business and iMFLUX. Swabs continue to be in short supply and are critical to fighting the COVID-19 pandemic. The companies believe the nasal swab’s unique features make it a better material choice for both PCR and antigen-based assays. These swabs reduce handling and lab processing cycle time and increase lab capacity as new home collection kits expand rapidly into the virus detection market.